Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. (VitaliThy)

2. november 2026 opdateret af: argenx

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.

The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.

The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.

More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

230

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Belgien
      • Ghent, Belgien, 9000
        • Rekruttering
        • Universitair Ziekenhuis Gent
        • Kontakt:
    • Oost-Vlass
      • Aalst, Oost-Vlass, Belgien, 9300
  • Bulgarien
      • Pazardzhik, Bulgarien, 4400
        • Rekruttering
        • Medical Center Tonus - 2013 OOD
        • Kontakt:
      • Plovdiv, Bulgarien, 4002
      • Sliven, Bulgarien, 8800
        • Rekruttering
        • Multiprofile Hospital for Active Treatment Hadzhi Dimitar OOD
        • Kontakt:
      • Sofia, Bulgarien, 1680
        • Rekruttering
        • Medical Center Kalimat
        • Kontakt:
      • Varna, Bulgarien, 9000
        • Rekruttering
        • Diagnostic Consultative Center Ekvita OOD
        • Kontakt:
      • Varna, Bulgarien, 9000
        • Rekruttering
        • MC Klinika Nova
        • Kontakt:
      • Veliko Tarnovo, Bulgarien, 5000
        • Rekruttering
        • Multi-Profile District Hospital for Active Treatment Dr. Stefan Cherkezov
        • Kontakt:
  • Canada
      • Surrey, Canada, V3T 2V6
        • Rekruttering
        • TLC Diabetes and Endocrinology Clinic
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Canada, H4J1E3
  • Danmark
    • Capital Region
      • Hillerød, Capital Region, Danmark, 3400
  • Georgien
      • Batumi, Georgien, 6000
        • Rekruttering
        • High Technology Hospital Medcenter LLC
        • Kontakt:
      • Tbilisi, Georgien, 0160
        • Rekruttering
        • LTD MediClub Georgia
        • Kontakt:
      • Tbilisi, Georgien, 0102
  • Grækenland
      • Athens, Grækenland, 15125
        • Rekruttering
        • Athens Medical Center
        • Kontakt:
      • Athens, Grækenland, 10676
        • Rekruttering
        • Evangelismos Hospital
        • Kontakt:
  • Italien
  • Japan
      • Iizuka, Japan, 820-8505
        • Rekruttering
        • Aso Iizuka Hospital
        • Kontakt:
      • Kawasaki, Japan, 211-8533
        • Rekruttering
        • Nippon Medical School Musashikosugi Hospital
        • Kontakt:
      • Kitakyushu, Japan, 807-8556
        • Rekruttering
        • Hospital of University of Occupational and Environmental Health
        • Kontakt:
      • Kyoto, Japan, 612-0861
        • Rekruttering
        • National Hospital Organization Kyoto Medical Center
        • Kontakt:
      • Nagasaki, Japan, 852-8501
        • Rekruttering
        • Nagasaki University Hospital
        • Kontakt:
      • Shibuya City, Japan, 150-8308
      • Yokohama, Japan, 224-8503
      • Yonago, Japan, 683-8504
    • Okayama-ken
      • Okayama, Okayama-ken, Japan, 700-8558
        • Rekruttering
        • Okayama University Hospital
        • Kontakt:
    • Tokyo
      • Bunkyō-Ku, Tokyo, Japan, 113-8431
        • Rekruttering
        • Juntendo University Hospital
        • Kontakt:
      • Ōta-ku, Tokyo, Japan, 143-8541
        • Rekruttering
        • Toho University Omori Medical Center
        • Kontakt:
  • Letland
      • Adazi, Letland, LV2164
        • Rekruttering
        • LTD M & M Centers
        • Kontakt:
      • Riga, Letland, 1012
        • Rekruttering
        • Veselibas centrs 4
        • Kontakt:
  • Litauen
      • Klaipėda, Litauen, LT-92288
        • Rekruttering
        • Klaipeda's University Hospital
        • Kontakt:
    • Kauno
      • Kaunas, Kauno, Litauen, 50161
        • Rekruttering
        • Hospital of Lithuanian University of Health Sciences Kaunas
        • Kontakt:
  • Polen
      • Bydgoszcz, Polen, 85-605
        • Rekruttering
        • Centrum Medyczne INTERCOR Sp. z o.o.
        • Kontakt:
      • Chrzanów, Polen, 32-500
      • Lublin, Polen, 20-412
      • Lublin, Polen, 20607
        • Rekruttering
        • Reumed Sp Z O.O.
        • Kontakt:
      • Warsaw, Polen, 01-691
      • Warsaw, Polen, 00-124
      • Warsaw, Polen, 02-677
        • Rekruttering
        • Etg Warszawa Sp. z o.o.
        • Kontakt:
      • Zamość, Polen, 22400
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 30-074
        • Rekruttering
        • Osrodek Medyczny Osteomed
        • Kontakt:
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polen, 40-600
  • Rumænien
      • Cluj-Napoca, Rumænien, 400396
        • Rekruttering
        • Cluj County Clinical Emergency Hospital
        • Kontakt:
    • Sibiu County
      • Sibiu, Sibiu County, Rumænien, 550245
        • Rekruttering
        • Clinical Hospital of Emergency Sibiu Ambulatory if Endocrinology
        • Kontakt:
  • Spanien
      • Alzira, Spanien, 46600
        • Rekruttering
        • Hospital Universitario De La Ribera
        • Kontakt:
      • Barcelona, Spanien, 08041
        • Rekruttering
        • Hospital de la Santa Creu i Sant Pau
        • Kontakt:
      • Móstoles, Spanien, 28935
        • Rekruttering
        • Hospital Universitario de Móstoles
        • Kontakt:
      • Santander, Spanien, 39011
        • Rekruttering
        • Instituto De Investigacion Marques De Valdecilla (IDIVAL
        • Kontakt:
      • Seville, Spanien, 41009
  • Tyskland
      • Magdeburg, Tyskland, 39110
        • Rekruttering
        • Institut fuer Praeventive Medizin & Klinische Forschung
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
  • Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening
  • Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening
  • Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening

Exclusion Criteria:

  • History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter)
  • History of RAI (radioactive iodine) therapy or received a total thyroidectomy
  • T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening
  • Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.
  • Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part A - efgartigimod PH20 SC PFS

Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Biologisk: efgartigimod PH20 SC

Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)
Placebo komparator: Part A - placebo PH20 SC PFS

Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Andet: Placebo PH20 SC

Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)
Eksperimentel: Part B - efgartigimod PH20 SC PFS

Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Biologisk: efgartigimod PH20 SC

Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)
Eksperimentel: Part B - placebo PH20 SC PFS

Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Andet: Placebo PH20 SC

Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)
Eksperimentel: Part C - efgartigimod PH20 SC PFS

Participants, will receive efgartigimod PH20 SC PFS in the part C open-label treatment period
Biologisk: efgartigimod PH20 SC

Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Tidsramme: up to 24 weeks (part A)

free triiodothyronine: [fT3]; free thyroxine: [fT4]; ATDs: antithyroid drugs
up to 24 weeks (part A)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to becoming euthyroid
Tidsramme: up to 24 weeks (part A) + up to 135 weeks
up to 24 weeks (part A) + up to 135 weeks
Efgartigimod serum concentrations over time
Tidsramme: up to 24 weeks (part A) + 72 weeks (part C)
up to 24 weeks (part A) + 72 weeks (part C)
Time to becoming euthyroid off ATDs in part A
Tidsramme: Up to 24 weeks (part A)

ATDs: antithyroid drugs
Up to 24 weeks (part A)
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Tidsramme: up to 24 weeks (part A)

MMI: methimazole (also known as thiamazole); CBZ carbimazole
up to 24 weeks (part A)
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Tidsramme: Up to 24 weeks (part A)

ULN : upper limit of normal; ATDs: antithyroid drugs
Up to 24 weeks (part A)
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Tidsramme: up to 24 weeks (part A)

TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs
up to 24 weeks (part A)
Time to becoming euthyroid off ATDs and TRAb seronegative
Tidsramme: up to 24 weeks (part A) + up to 135 weeks

ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies
up to 24 weeks (part A) + up to 135 weeks
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Tidsramme: up to 24 weeks

ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ carbimazole
up to 24 weeks
Time to having fT3 and fT4 levels within normal ranges among participants who had fT3 and/or fT4 more than the ULN at baseline (part A)
Tidsramme: up to 24 weeks (part A)

ULN : upper limit of normal
up to 24 weeks (part A)
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Tidsramme: up to 24 weeks (part A)

TSH: thyroid-stimulating hormone; LLN: lower limit of normal
up to 24 weeks (part A)
Percentage of participants who remain euthyroid off ATDs
Tidsramme: Up to 50 weeks (part B)

ATDs: antithyroid drug
Up to 50 weeks (part B)
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day
Tidsramme: Up to 50 weeks (part B)

ATDs: antithyroid drug
Up to 50 weeks (part B)
Percentage of participants who remain euthyroid without ATDs
Tidsramme: up to 98 weeks (part B)

ATDs: antithyroid drug
up to 98 weeks (part B)
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Tidsramme: up to 74 weeks (part B) + up to 135 weeks

ATDs: antithyroid drug
up to 74 weeks (part B) + up to 135 weeks
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Tidsramme: up to 72 weeks (part C)

ATDs: antithyroid drug
up to 72 weeks (part C)
Incidence of AEs and SAEs
Tidsramme: up to 135 weeks

AEs: adverse events ; SAEs: serious adverse events
up to 135 weeks
Change in ThyPRO-39 over time
Tidsramme: Up to 135 weeks

The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status
Up to 135 weeks
Change in PROMIS-PF10a over time
Tidsramme: up to 135 weeks

The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self- administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.
up to 135 weeks
Percentage change from baseline in total IgG levels in serum over time
Tidsramme: up to 98 weeks

IgG: immunoglobulin G
up to 98 weeks
Percentage change from baseline in TRAb serum levels over time
Tidsramme: up to 135 weeks

TRAb: anti-TSHR autoantibodies
up to 135 weeks
Incidence of ADA against efgartigimod in serum
Tidsramme: up to 24 weeks (part A) + up to 135 weeks

ADA: antidrug antibody(ies)
up to 24 weeks (part A) + up to 135 weeks
Incidence of antibodies against rHuPH20 in plasma
Tidsramme: up to 24 weeks (part A) + Up to 135 weeks

rHuPH20: recombinant human hyaluronidase PH20
up to 24 weeks (part A) + Up to 135 weeks
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
Tidsramme: up to 24 weeks (part A) + up to 135 weeks

NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20
up to 24 weeks (part A) + up to 135 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

argenx

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. juni 2026

Primær færdiggørelse (Anslået)

1. juni 2028

Studieafslutning (Anslået)

1. maj 2030

Datoer for studieregistrering

Først indsendt

13. maj 2026

Først indsendt, der opfyldte QC-kriterier

13. maj 2026

Først opslået (Faktiske)

19. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ARGX-113-25-GRD-3001
  • 2025-523333-26-00 (Ctis)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner